Sign In
Buy BMY
$54.72
+0.260 (+0.477%)
At Close: Jun 03, 2026
Will Positive Camzyos Data Strengthen BMY's Cardiovascular Portfolio?
04:00pm, Monday, 30'th Mar 2026
BMY's Camzyos shows strong late-stage results in adolescent heart disease, boosting hopes for expanded use as cardiovascular portfolio faces mixed developments.
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ACC--BMS Presents Positive Results from Phase 3 SCOUT-HCM Trial Demonstrating Efficacy and Safety of Camzyos in Adolescents with Symptomatic oHCM.
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Cobenfy--Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy.
Bristol Myers Squibb Company $BMY Position Raised by Czech National Bank
04:45am, Thursday, 26'th Mar 2026
Czech National Bank lifted its position in shares of Bristol Myers Squibb Company (NYSE: BMY) by 3.8% in the undefined quarter, according to its most recent disclosure with the SEC. The fund owned 536
Bristol Myers Squibb (BMY) Surpasses Market Returns: Some Facts Worth Knowing
06:46pm, Wednesday, 25'th Mar 2026
In the closing of the recent trading day, Bristol Myers Squibb (BMY) stood at $58.94, denoting a +2.7% move from the preceding trading day.
Will the Recent Label Expansion of BMY's Opdivo Boost Its IO Franchise?
01:05pm, Wednesday, 25'th Mar 2026
Bristol Myers Squibb's Opdivo expansions highlight pharma companies' push to grow oncology franchises amid rising competition and pipeline innovation.
Bristol-Myers Squibb: Dividend/Portfolio Renewal Thesis Remains Promising
12:36pm, Tuesday, 24'th Mar 2026
Bristol-Myers Squibb's new Opdivo Qvantig injectable delivery is expected to secure additional 20Y patent protection, with their efforts to drive physician adoption before 2028 likely to temper top-li
What Is Considered a Good Stock Dividend? 2 Healthcare Stocks Fit the Bill.
07:06am, Tuesday, 24'th Mar 2026
Both companies have distributions boasting above-average yields. One is even a Dividend King.
Should You Buy Bristol Myers Squibb Stock for Its 4.4%-Yielding Dividend?
04:30pm, Monday, 23'rd Mar 2026
Bristol Myers has historically been a good and safe dividend stock to own. A strong track record, however, doesn't guarantee future payments will be safe.
FDA Approves BMY's Opdivo Label Expansion in Classical Hodgkin Lymphoma
12:30pm, Monday, 23'rd Mar 2026
Bristol Myers expands Opdivo's reach with new U.S. and EU approvals in Hodgkin lymphoma, strengthening its immunotherapy leadership and growth outlook.
Bristol-Myers Squibb: An Attractive High-Yield Stock Amid Market Uncertainty
08:00am, Monday, 23'rd Mar 2026
Bristol-Myers Squibb remains a "Buy," offering a high dividend and free cash flow yield amid recent market pullback. BMY's Growth Portfolio drove 16% YoY net sales growth, offsetting Legacy Portfolio
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ACC26--BMS Reinforces Leadership in oHCM with New Camzyos Data at American College of Cardiology Annual Scientific Session & Expo 2026 (ACC.26).
1 High-Yield Dividend Stock That's Too Cheap to Ignore
03:00pm, Saturday, 21'st Mar 2026
Bristol Myers Squibb operates in a defensive industry that can navigate challenging periods fairly well. Despite some recent headwinds, the company could perform well over the long run.
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CheckMate--Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo® (nivolumab).
Will the Recent Label Expansion of BMY's Sotyktu Boost Its Prospects?
03:50pm, Friday, 20'th Mar 2026
BMY's Sotyktu PsA approval boosts its immunology push, expands market reach, and sharpens its competitive stance amid pressure from legacy drug declines.
